Depressive Disorders: Recent submissions
Now showing items 1-20 of 111
-
Pramipexole for the Treatment of Depression: Efficacy and Mechanisms
(2023-11)Dopaminergic mechanisms are a plausible treatment target for patients with clinical depression but are relatively underexplored in conventional antidepressant medications. There is continuing interest in the potential ... -
Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
(2023-10)Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways may affect ... -
Towards precision in the diagnostic profiling of patients: leveraging symptom dynamics in the assessment of major depressive disorder
(2023-08)Major depressive disorder (MDD) is a heterogeneous mental disorder. International guidelines present overall symptom severity as the key dimension for clinical characterisation. However, additional layers of individual ... -
Cognitive predictors of stress-induced mood malleability in depression
(2023-09)Basic attentional control, negative biases in attention and interpretation, and rumination are all cognitive processes associated with depression; however, less is known about their predictive role in depressive mood ... -
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder
(2023-07)JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1β/IL-18 release. In healthy volunteers, JNJ-54175446 suppressed peripheral interleukin (IL)-1β release, and attenuated ... -
Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation
(2023-07)There is concern regarding the impact of selective serotonin reuptake inhibitors (SSRIs) on suicidal behaviour. Using the target trial framework, we investigated the effect on suicidal behaviour of SSRI treatment following ... -
Measuring affect dynamics: An empirical framework
(2023-04)A fast-growing body of evidence from experience sampling studies suggests that affect dynamics are associated with well-being and health. But heterogeneity in experience sampling approaches impedes reproducibility and ... -
A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression
(2023-06)A recent “umbrella” review examined various biomarkers relating to the serotonin system, and concluded there was no consistent evidence implicating serotonin in the pathophysiology of depression. We present reasons for why ... -
An online experimental medicine trial on the effect of 28-day simvastatin administration on emotional processing, reward learning, working memory and salivary cortisol in healthy volunteers at risk for depression: OxSTEP protocol
(2023-06)Background: Evidence suggests inflammation may be a key mechanism by which psychosocial stress, including loneliness, predisposes to depression. Observational and clinical studies have suggested simvastatin, with its ... -
Machine learning prediction will be part of future treatment of depression
(2023-02)Machine learning (ML) is changing the way that medicine is practiced. While already clinically utilised in diagnostic radiology and outcome prediction in intensive care unit, ML approaches in psychiatry remain nascent. ... -
Fifty years on: Serotonin and depression
(2023-03)It has been over 50 years since the original serotonin hypothesis was proposed by the British Psychiatrist Alec Coppen. Recently, some authors have questioned the validity of the hypothesis. In this narrative review, we ... -
Predicting Antidepressant Treatment Response Using Functional Brain Controllability Analysis
(2023-03)Introduction: For decades, predicting response to the antidepressant medication has been a critical unmet need in depression treatment in clinic, and a technical challenge in depression research. Methods: In this study, ... -
Mortality in psychotic depression: 18-year follow-up study
(2022-10)Background Evidence on the role of co-occurring psychiatric disorders in mortality associated with psychotic depression is limited. Aims To estimate the risk of cause-specific mortality in psychotic depression compared ... -
Statins in depression: a repurposed medical treatment can provide novel insights in mental health
(2022-08)Depression has a large burden, but the development of new drugs for its treatment has proved difficult. Progresses in neuroscience have highlighted several physiopathological pathways, notably inflammatory and metabolic ... -
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents
(2022-05)Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal. Little is known however about how current pharmacotherapies act to modulate ... -
No Association Between Amygdala Responses to Negative Faces and Depressive Symptoms: Cross-Sectional Data from 28,638 Individuals in the UK Biobank Cohort
(2022-07)In this Priority Data Letter, we report on the largest study to date to test the association between amygdala reactivity and depressive symptoms based on UK Biobank data. For transparency, we initially set out to investigate ... -
Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment
(2021-10)Background: Clinical trials with putative antidepressants can be difficult to execute as it can take up to 8 weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation ... -
Investigating inflammation in depression in the chronically ill: Theoretical model and perspectives
(2022-07)Inflammation is a risk factor for chronic physical illnesses. Evidence is building that inflammation is also a risk factor for mental illnesses making inflammation a common mechanism which could explain the high comorbidity ... -
Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals
(2022-07)Background: Non-serious adverse events (NSAEs) should be captured and reported because they can have a significant negative impact on patients and treatment adherence. However, the reporting of NSAEs in randomised controlled ... -
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis
(2022-06)Background: Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear. Aims: To find the optimal dosage of brexpiprazole as augmentation ...
